Sharemaestro company-news research for Hanall Biopharma Co., Ltd. (009420), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
KSC
South Korea
Insufficient evidence
Company news sentiment
009420 news sentiment
Hanall Biopharma Co., Ltd.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone50Neutral is 50
No current sentiment signal
0/100 evidence confidence
0% direct company focus
0 current stories across 0 publishers
Current company news
The current company-level signal is not yet measurable
Available headlines do not meet the required combination of freshness, direct relevance and independent source depth. The neutral score is a withheld classification, not a neutral forecast.
Available context
+24.7% over one week, -5.7% over four weeks, trend inactive, and materially above fair value.
Why classification is withheld
No current company-specific story carries enough weight to establish a direct signal.
Evidence confidence is 0/100, below the threshold for a firm classification.
50/100
Weighted toneNo current sentiment signal
0/100
Evidence confidencethin evidence
0%/100
Company focus0 direct stories
N/A/100
Evidence agreementrequires at least 2 stories
News history
Tone and story flow over 21 days
No measurable trajectory yet
The chart will begin when a dated headline passes the relevance and freshness controls.
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth0
0 effective storiesSource breadth0
0 independent publishersDirect relevance0
company-specific evidence shareFreshness0
recency-weighted evidenceAgreement0
requires at least 2 storiesSource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
No sufficiently fresh, directly relevant company news is available for a price comparison.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Insufficient evidence
News subjects
What is shaping the score
Catalyst structure will appear as classified company evidence builds.
Source mix
Where the evidence comes from
No current publisher evidence is available.
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
No qualifying current company evidence
No sufficiently fresh and relevant headline currently passes the evidence rules. Earlier readings remain in the timeline and are not relabelled as a neutral current outlook.
Earlier company news
009420 news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
12
2026
팜이데일리ArchivedNeutral tone
Trust Dividend for HanAll, Valuation Penalty for Peptron·Caregen[K-Bio Pulse]
- Published
- 12 Aug 2026 10:29
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
08
2026
bioworld.comArchivedNeutral tone
Daewoong takes over Turn Bio’s longevity platform from Hanall
- Published
- 8 Aug 2026 00:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
05
2026
TradingViewArchivedNeutral tone
Hanall Biopharma Co., Ltd. Revenue Breakdown – KRX:009420
- Published
- 5 Aug 2026 12:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
27
2026
TradingViewArchivedNeutral tone
ETFs Investing in Hanall Biopharma Co., Ltd. Stocks
- Published
- 27 Jul 2026 06:58
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
21
2026
TradingViewArchivedNeutral tone
Enterprise value to EBIT forward of Hanall Biopharma Co., Ltd. – KRX:009420
- Published
- 21 Jul 2026 12:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
16
2026
TradingViewArchivedNeutral tone
Enterprise value to revenue forward of Hanall Biopharma Co., Ltd. – KRX:009420
- Published
- 16 Jul 2026 16:18
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
13
2026
TradingViewArchivedNeutral tone
Price to sales forward of Hanall Biopharma Co., Ltd. – KRX:009420
- Published
- 13 Jul 2026 12:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
TradingViewArchivedNeutral tone
Price to book forward of Hanall Biopharma Co., Ltd. – KRX:009420
- Published
- 10 Jul 2026 13:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
09
2026
TradingViewArchivedNeutral tone
Enterprise value to EBITDA forward of Hanall Biopharma Co., Ltd. – KRX:009420
- Published
- 9 Jul 2026 12:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
03
2026
TradingViewArchivedNeutral tone
Hanall Biopharma Co., Ltd. Actuals & Estimates (KRX:009420)
- Published
- 3 Jul 2026 14:48
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.